Learning
Jo Freeman Reviews Elizabeth Warren's New Book: Persist ("I have a plan for that")
Jo Freeman writes: If you enjoyed listening to Elizabeth Warren during the 2019/20 Presidential debates or if you applauded her on the campaign trail, you will love this book. It’s one very long campaign speech. In six chapters she entertains readers with stories of her youth, her family, her dog, her plans, her policy proposals, and a few insights... Not until the final chapter on being “A Woman” does she begin to tie her experiences together. She ran into a lot of glass ceilings and broke some of them, but never escaped the “discrimination that lasts a lifetime.” She talks about care giving and abortion, as well as the consequences of unequal pay and limited job opportunities for women... As her final story, Warren writes about a little girl she met on the selfie line in St. Paul Minnesota, in 2019. That girl told her “You better win... I’ve been waiting for a girl president since.... since... since kindergarten.” more »
91.0% Efficacy In Preventing Symtomatic Disease: US Clinical Trial Results Show Novavax Vaccine is Safe and Prevents COVID-19
Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States and Mexico show that the investigational vaccine known as NVX-CoV2373 demonstrated 90.4% efficacy in preventing symptomatic COVID-19 disease. The candidate showed 100% protection against moderate and severe disease. In people at high risk of developing complications from COVID-19 (people 65 years or older and people under age 65 with certain comorbidities or with likely regular exposure to COVID-19), the vaccine showed 91.0% efficacy in preventing symptomatic COVID-19 disease. more »
Kaiser Family Foundation: FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
"The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S.— and now we’re about to find out. After a nearly 20-year dry spell in new treatments for Alzheimer’s disease, the Food and Drug Administration (FDA) just approved a new Alzheimer’s medication, Aduhelm (aducanumab), developed by Biogen, with an expected annual price tag of $56,000. While the scientific community debates the evidence of the effectiveness of this new drug, the FDA’s decision raises hope for Alzheimer’s patients and their families, along with serious cost concerns for patients and payers, particularly Medicare." more »
U.S. Government Accountability Office: Science & Tech Spotlight: Renewable Ocean Energy
A Century of Non-Partisan Fact-Based Work: What is it? Renewable ocean energy (or, simply, ocean energy), is energy derived from the ocean's movement, or from its physical and chemical state. In the United States, ocean energy can be generated from waves, tides, and currents, as well as ocean temperature differences. The National Renewable Energy Laboratory estimates that if fully utilized, ocean energy resources in the U.S. could provide the equivalent of over half of the electricity that the country generated in 2019. U.S. government and industry stakeholders predict that ocean energy will likely be first used to provide power for energy and water needs of island and coastal communities and offshore activities. more »